Iecure
3 known investors
Find your way into Iecure
120 people in our graph share verified history with the Iecure team — schools, employers, funds. One of them is your warm intro.
David Schenkeinunlockedknows Gabriel M. Cohn · together at Upstate Medical University (overlapped)
×7knows the team · via Isenberg School of Management, UMass Amherst
×2knows the team · via Brooklyn College
knows the team · via Upstate Medical University
knows the team · via The National Institutes of Health
iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
Founders & leadership
JM
James M. WilsonScientific Founder
JT
Joseph TruittinCEO & Board Member
PF
Paul FirutainCOO
AM
Alex MonteithChief Business Officer
DG
David GarrettinCFO
GM
Gabriel M. CohninChief Medical OfficerGabriel M. Cohn is Chief Medical Officer at iECURE, a clinical-stage biotech company developing in vivo genome editing therapies for rare genetic diseases. A physician with board certification in Obstetrics, Gynecology, and Clinical Genetics, an MBA, and prior experience in translational medicine and rare disease development across gene therapy and enzyme replacement therapy programs.
Investors · 3
Frequently asked questions
- What does Iecure do?
- iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
- Who founded Iecure?
- Iecure was founded by James M. Wilson.
- Who are Iecure's investors?
- Iecure's investors include OrbiMed, LYFE Capital, Versant Ventures.